ALNY   $244.91  -0.77% Market Closed After Close 244.4 -0.21%

Alnylam Pharmaceuticals Inc
Total Cash 2.62B
totalCashPerShare 20.444
EBITDA 157.97M
Total Debt 2.71B
quickRatio 2.781
currentRatio 3.007
Total Revenue 2.34B
debtToEquity
Revenue/Share 18.617
ROA 0.01731
ROE
grossProfits
freeCashflow 424.34M
operatingCashflow 372.26M
earningsGrowth
revenueGrowth 1.07
grossMargins 0.86998004
ebitdaMargins 0.067379996
operatingMargins 0.07368
profitMargins -0.03111
enterpriseValue 36.22B
forwardPE -193.81885
floatShares 127.84M
sharesOutstanding 128.98M
sharesShort 4.84M
sharesShortPriorMonth 4.45M
dateShortInterest
sharesPercentSharesOut 0.04%
heldPercentInsiders 0.00%
heldPercentInstitutions 0.96%
Short Ratio help_outline 7.60%
shortPercentOfFloat 0.04%
impliedSharesOutstanding
bookValue -1.754
Price To Book help_outline
earningsQuarterlyGrowth
netIncomeToCommon -72.94M
trailingEps -0.56%
forwardEps -1.38%
enterpriseToEbitda 229.29
lastDividendValue
lastDividendDate
currentQuarterEstimate -0.79 4Q 2024
institutionsCount 849
lastUpdated Nov. 1, 2024, 6:24 p.m.